Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity

Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity

Abstract Alcohol Use Disorder (AUD) contributes significantly to global mortality. GLP-1 (Glucagon-like peptide-1) and GLP-1/GIP (Glucose-dependent Insulinotropic Polypeptide) agonists, FDA-approved for managing type 2 diabetes and obesity, where the former has shown to effectively reduce the consum...

Full description

Bibliographic Details
Main Authors: Fatima Quddos, Zachary Hubshman, Allison Tegge, Daniel Sane, Erin Marti, Anita S. Kablinger, Kirstin M. Gatchalian, Amber L. Kelly, Alexandra G. DiFeliceantonio, Warren K. Bickel
Format: Article
Language:English
Published: Nature Portfolio 2023-11-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-48267-2

Internet

https://doi.org/10.1038/s41598-023-48267-2

Similar Items